^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersCOMPANY:University of Washington
i
Other names: University of Washington | University of Washington School of Medicine | UWSOM | UW Medicine | UW Medicine Memory and Brain Wellness Center | Medicine Memory and Brain Wellness Center | Memory & Brain Wellness Center | Univ. of Washington | University of Washington Seattle | University of Washington (UW) | UW-Seattle | University of Washington-Seattle | University of Washington,Seattle | University of Washington at Seattle | Univ of Washington
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related tests:
Evidence
News
Evidence Level:
Sensitive: C4 – Case Studies
[BRCA2 mutation-Prostate Cancer-nivolumab + ipilimumab]
Source:
Test:
UW-Oncoplex™
Title:
LB004 - Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
Published date:
04/09/2021
Excerpt:
Pts with mCRPC who progressed following ≥1 line of therapy and ImS+ were eligible. ImS+ was defined by ≥1 of the following: 1) mismatch repair deficient (MMRD) by immunohistochemistry (IHC); 2) DNA damage repair deficient (DDRD) excluding MMRD, detected by the UW-OncoPlex targeted exome sequencing assay...The overall CRR was 9/35 (26%, 95%CI 12-43%).... NIVO + IPI demonstrated significant activity in biomarker selected, pre-treated pts with mCRPC.
Evidence Level:
Sensitive: C4 – Case Studies
[CDK12 mutation-Prostate Cancer-nivolumab + ipilimumab]
Source:
Test:
UW-Oncoplex™
Title:
LB004 - Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
Published date:
04/09/2021
Excerpt:
Pts with mCRPC who progressed following ≥1 line of therapy and ImS+ were eligible. ImS+ was defined by ≥1 of the following: 1) mismatch repair deficient (MMRD) by immunohistochemistry (IHC); 2) DNA damage repair deficient (DDRD) excluding MMRD, detected by the UW-OncoPlex targeted exome sequencing assay...The overall CRR was 9/35 (26%, 95%CI 12-43%).... NIVO + IPI demonstrated significant activity in biomarker selected, pre-treated pts with mCRPC.
